Forcefield Therapeutics

Forcefield Therapeutics is owned by Syncona.

Syncona is one of the...

• FTSE 350.

Syncona is a company listed under the stock ticker SYNC (GB).

Syncona has a direct presence in 3 countries.

Syncona has 13 subsidiaries including Achilles Therapeutics, Anaveon and Autolus Therapeutics.

They are in:

• Biotechnology86%
• Holding7%
• Other7%

Acquisition, funding and merger involving Syncona.

• Syncona has announced the acquisition of Beacon Therapeutics  (posted on October 28 2022).

View the org chart displaying its 4 main executives

Most searched biographies at Forcefield Therapeutics

• John Tsai, Chief Executive Officer
• Alice Renard, Board Director
• Elisa Petris, Board Director

Popular executive movements at Forcefield Therapeutics

• John Tsai has joined the company as Chief Executive Officer  (posted on October 1 2023).

Create your alert
to follow the executive moves at Forcefield Therapeutics.

Syncona has 2,291 competitors including Lonza (Switzerland), Eurofins (Luxembourg) and Adaptive Phage Therapeutics (United States (USA)).

Popular M&A news in Biotechnology

• Lycia Therapeutics has just announced a $107 Million fundraising (posted on May 15 2024).
• Attovia Therapeutics has just announced a $150 Million fundraising (posted on May 14 2024).
• Bruker has announced the acquisition of NanoString Technologies  (posted on May 13 2024).

Popular contacts in Biotechnology

• Ali Behbahani - Non-Executive Director at Adaptimmune Therapeutics
• Carl Gordon - Director at Adicet Bio
• Vik Bajaj - Director at Interline Therapeutics

Learn more about the Biotechnology industry >

Press releases by Forcefield Therapeutics

Social media about Forcefield Therapeutics

• Forcefield Therapeutics on Wikipedia, Google News & Yahoo Finance
• Forcefield Therapeutics on LinkedIn, Twitter & YouTube

Contact by email its executives including John Tsai

Call Forcefield Therapeutics at +44 203...

View the org chart

Register to receive your alert

Report an error